Our Pipeline
Vaccinex is advancing clinical programs centered on Semaphorin 4D (SEMA4D), a novel therapeutic target that plays a critical role in the progression of neurodegenerative diseases and cancer. Pepinemab, our lead monoclonal antibody drug candidate targeting SEMA4D, is being evaluated for its safety and potential to improve outcomes in patients with Alzheimer’s disease, Huntington’s disease, head and neck cancer, melanoma, and breast cancer.
Pre-Clinical
Phase 1
Phase 2
Pepinemab
Alzheimer's Disease
Pending
Phase 2 Trial
Pending
Pepinemab
Alzheimer's Disease
Completed
With support from the Alzheimer's Association & the Alzheimer's Drug Discovery Foundation
Phase 2 Trial
Completed
Pepinemab
Huntington's Disease
Completed
Phase 2 Trial
Completed
Pre-Clinical
Phase 1
Phase 2
Pepinemab + Pembrolizumab
Completed
KEYNOTE-B84
In partnership with Merck Sharp & Dohme
Phase 2 Trial
Completed
Pepinemab + Avelumab
Completed
CLASSICAL-Lung
In partnership with Merck KGaA Darmstadt
Phase 1b/2 Trial
Completed
Pepinemab + Avelumab
Completed
In partnership with
Merck KGaA Darmstadt,
University of Rochester,
Gateway Discovery Foundation
Phase 1b/2 Trial
Completed
Pepinemab + Nivolumab and/or Ipilimumab
Investigator-sponsored trial
Emory University with
Bristol Myers Squibb
Completed
Phase 1 Trial
Completed
Pepinemab + Nivolumab and/or Ipilimumab
Completed
Investigator-sponsored trial
Emory University with
Bristol Myers Squibb
Phase 2 Trial
Completed
Pepinemab
Completed
Investigator-sponsored trial
NCI in partnership with the
Children's Oncology Group
Phase 1/2 Trial
Completed
Pepinemab + Trastuzumab
+DC Vaccine
Investigator-sponsored trial
H. Lee Moffitt Cancer Center
Enrollment complete
Phase 1 Trial
Enrollment Complete
Research and Development
Vaccinex has several antibodies discovered using ActivMab Technology that are available for licensing.